CNBC 快讯 7月9日 07:34 阿斯利康心脏药物试验未达终点导致股价重挫9% AstraZeneca stock dives 9% after heart drug trial misses target FG 100 读报告 →
CNBC 快讯 7月11日 05:00 阿斯利康试验失败：管线溢价是否正在变得脆弱？ AstraZeneca's trial flop raises a bigger question: Is its pipeline premium becoming more vulnerable? For years, AstraZeneca has commanded one of the richest valuations among large European pharma companies on the assumpti… FG 100 读报告 →